Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy.

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]

It needed to post a blowout quarter instead of the good one it delivered.

Liquidia stock has delivered an extremely strong run over the past few years, yet the valuation checks now suggest investors are dealing with a mixed picture rather than a clear bargain or clear overvaluation. After such a sharp move, the recent pullback raises the question of how much of the good news is already reflected in the current price. Liquidia has returned about 28.7x over the last 5 years, which puts recent pricing under closer scrutiny for anyone considering fresh...

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.

Liquidia Corp (LQDA) posts $170.4 million in quarterly sales and projects over $1 billion in 2027 revenue amid pipeline advancements.

Moby summary of Liquidia Corporation's Q2 2026 earnings call

Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.

Liquidia (NASDAQ:LQDA) reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline. Chief Executive Officer Roger Jeffs said the company had received approximately 5,900 uniq

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

Net product sales for the second quarter surged to $170.4 million from $6.5 million last year, due to higher Yutrepia sales volumes.

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +5.71% and +3.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Corporation (NASDAQ:LQDA) shares fell 4. 58% in premarket trading on Wednesday after the biopharmaceutical company reported second-quarter earnings below Wall Street expectations, despite revenue coming in slightly ahead of forecasts.

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +15.70% and +148.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.

Why Liquidia’s latest profitability milestone matters Liquidia (LQDA) recently reported its third consecutive profitable quarter, supported by real world demand for its FDA approved pulmonary hypertension therapy YUTREPIA and an expanded US$100,000,000 financing agreement with HealthCare Royalty. See our latest analysis for Liquidia. Liquidia’s recent news has arrived alongside strong share price momentum, with a 90 day share price return of 113.29% and a year to date share price return of...

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.

Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Lenovo, Victoria's Secret and Liquidia have been highlighted in this Investment Ideas article.

In recent months, Liquidia Corporation reported its third consecutive profitable quarter as rapid commercial uptake of its FDA-approved pulmonary hypertension therapy YUTREPIA has supported stronger sales and earnings. What stands out is that profitability is now being driven by real-world demand for YUTREPIA, underpinning expanding earnings estimates and increased institutional attention to the company’s fundamentals. We’ll now examine how YUTREPIA’s rapid commercial ramp and emerging...

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

Lenovo Group, Victoria's Secret and Liquidia Corporation are three stocks from very different industries benefitting from the same catalysts.

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.

Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.

Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.